血交换与白蛋白替代剂对白蛋白功能和器官功能障碍在急性-慢性肝衰竭中的作用
Javier Fernández1,2, Miquel Lozano3, Mireia Torres4
1Liver ICU, Liver Unit, Hospital Clinic, IDIBAPS and CIBEREHD, Barcelona, Spain.
JHEP reports : innovation in hepatology
|March 28, 2024
概括
与5%白蛋白 (PE-A5%) 的血交换改善了急性至慢性肝衰竭 (ACLF) 患者的白蛋白功能和器官功能. 这种安全的程序对ACLF患者的循环,,大脑和肝功能产生了积极的影响.
科学领域:
- 肝病学和重症监护医学 肝病学和重症监护医学
- 基于等离子体的治疗方法
- 在肝衰竭中提供器官支持.
背景情况:
- 急性至慢性肝衰竭 (ACLF) 呈现出对有效治疗的重大未满足需求.
- ACLF的特点是系统性炎症,多器官衰竭和高死亡率.
- 现有的ACLF治疗方法在改善患者的治疗结果方面有效性有限.
研究的目的:
- 评估与5%白蛋白 (PE-A5%) 的血交换在改善白蛋白功能能力方面的有效性.
- 评估PE-A5%对被诊断为ACLF的患者器官功能障碍的影响.
- 在ACLF治疗的背景下确定PE-A5%的安全概况.
主要方法:
- 一个单中心,前性,开放标签,非受控的II期研究招募了十名患有ACLF的成年患者.
- 患者在10天内接受了6次PE-A5%的治疗,随后进行1个月的随访.
- 评估包括白蛋白功能能力,循环,,大脑和肝功能以及全身炎症.
主要成果:
- PE-A5%显著提高了白蛋白结合能力,脂肪酸结合能力和抗氧化能力.
- 治疗导致增强本源性白蛋白水平和改善全身血液动力学.
- 在功能,肝脏脑病等级,肝脏参数和炎症标志物中观察到显著改善.
结论:
- 用5%白蛋白 (PE-A5%) 进行血交换是ACLF患者的安全程序.
- PE-A5%对白蛋白功能和多个器官系统产生积极影响.
- 这些发现表明,PE-A5%可能对ACLF的生存有有益影响.
相关概念视频
01:29Drug Distribution: Plasma Protein Binding
5.6K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
5.6K
01:09Hepatic Drug Clearance: Effect of Protein Binding
194
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
194
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
57
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
57
01:11Renal Failure: Dose Adjustments
88
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
88
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
156
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
156
01:27Dialysis
307
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
307